KR20000068415A - 매트릭스 메탈로프로테이나제 억제용 화합물 및 방법 - Google Patents

매트릭스 메탈로프로테이나제 억제용 화합물 및 방법 Download PDF

Info

Publication number
KR20000068415A
KR20000068415A KR1019997001757A KR19997001757A KR20000068415A KR 20000068415 A KR20000068415 A KR 20000068415A KR 1019997001757 A KR1019997001757 A KR 1019997001757A KR 19997001757 A KR19997001757 A KR 19997001757A KR 20000068415 A KR20000068415 A KR 20000068415A
Authority
KR
South Korea
Prior art keywords
dibenzofuran
sulfonylamino
acid
phenyl
hexanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1019997001757A
Other languages
English (en)
Korean (ko)
Inventor
죠셉 아르만드 피카드
드라고 로버트 슬리스코빅
Original Assignee
로즈 암스트롱, 크리스틴 에이. 트러트웨인
워너-램버트 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로즈 암스트롱, 크리스틴 에이. 트러트웨인, 워너-램버트 캄파니 filed Critical 로즈 암스트롱, 크리스틴 에이. 트러트웨인
Publication of KR20000068415A publication Critical patent/KR20000068415A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1019997001757A 1996-09-04 1997-09-02 매트릭스 메탈로프로테이나제 억제용 화합물 및 방법 Abandoned KR20000068415A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2506396P 1996-09-04 1996-09-04
US5571497P 1997-08-07 1997-08-07
US60/025,063 1997-08-07
US60/055,714 1997-08-07

Publications (1)

Publication Number Publication Date
KR20000068415A true KR20000068415A (ko) 2000-11-25

Family

ID=26699217

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997001757A Abandoned KR20000068415A (ko) 1996-09-04 1997-09-02 매트릭스 메탈로프로테이나제 억제용 화합물 및 방법

Country Status (10)

Country Link
US (1) US6294674B1 (cg-RX-API-DMAC10.html)
EP (1) EP0929542A1 (cg-RX-API-DMAC10.html)
JP (1) JP2002514180A (cg-RX-API-DMAC10.html)
KR (1) KR20000068415A (cg-RX-API-DMAC10.html)
AU (1) AU736347B2 (cg-RX-API-DMAC10.html)
BR (1) BR9712794A (cg-RX-API-DMAC10.html)
CA (1) CA2256631A1 (cg-RX-API-DMAC10.html)
HR (1) HRP970474B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ333064A (cg-RX-API-DMAC10.html)
WO (1) WO1998009957A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
NZ325939A (en) * 1996-01-23 2000-06-23 Shionogi & Co Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives
MXPA99001974A (es) * 1996-12-09 2002-03-27 Warner Lambert Co Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular.
OA11589A (en) 1998-07-30 2004-07-30 Warner Lambert Co Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases.
US6350885B1 (en) 1998-07-30 2002-02-26 Warner-Lambert Company Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
WO2000015213A1 (en) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure
CN1229339C (zh) * 2000-03-27 2005-11-30 斯克里普斯研究学院 抑制血管生成和肿瘤生长的化合物,含有该化合物的药用制剂,以及该化合物的制药用途
GB2365425A (en) * 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20030129672A1 (en) * 2001-08-29 2003-07-10 Dyer Richard Dennis Method for identifying metalloenzyme inhibitors
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CN1318411C (zh) * 2005-03-21 2007-05-30 中国海洋大学 氢化轮枝霉酮类化合物及其制备方法和用途
AU2006332694A1 (en) * 2005-12-30 2007-07-12 Alantos Pharmaceuticals, Holding, Inc. Substituted bis-amide metalloprotease inhibitors
EP2074107A2 (en) * 2006-10-27 2009-07-01 Wyeth a Corporation of the State of Delaware Tricyclic compounds as matrix metalloproteinase inhibitors
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
AR066412A1 (es) * 2007-05-04 2009-08-19 Wyeth Corp Derivados de dibenzofurano y dibenzotiofeno, composiciones farmaceuticas que los contienen y usos en patologias tales como trastornos oseos, crecimiento de tumores, diabetes y obesidad.
CA2692004C (en) * 2007-06-15 2013-04-09 Board Of Regents, The University Of Texas System Methods and compositions to inhibit edema factor and adenylyl cyclase
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Eg5阻害剤
TWI747873B (zh) * 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
WO2021147882A1 (zh) * 2020-01-21 2021-07-29 深圳信立泰药业股份有限公司 一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2065966C3 (de) 1969-09-06 1978-11-16 Ajinomoto Co., Inc., Tokio N-Fluorenyl-sulfonyl-aminocarbonsäuren sowie diese enthaltende Mittel
US3845097A (en) 1969-09-06 1974-10-29 Ajinomoto Kk N-substituted amino acids and novel ester
US4097472A (en) 1974-11-08 1978-06-27 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
DE2236876C3 (de) * 1971-08-19 1981-02-12 Ajinomoto Co., Inc., Tokio N-Substituierte Aminocarbonsäuren und diese Verbindungen enthaltende Arzneimittel
EP0183271B1 (en) * 1984-11-30 1990-05-16 Shosuke Okamoto Lysin derivative and proteinase inhibitor
PH31294A (en) * 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5627206A (en) 1995-06-02 1997-05-06 Warner-Lambert Company Tricyclic inhibitor of matrix metalloproteinases
US5665764A (en) 1995-06-02 1997-09-09 Warner-Lambert Company Tricyclic inhibitors of matrix metalloproteinases
DK0828726T3 (da) 1995-06-02 2002-01-21 Warner Lambert Co Tricykliske inhibitorer af matrixmetalloproteinaser
SK282833B6 (sk) 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
NZ325939A (en) 1996-01-23 2000-06-23 Shionogi & Co Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives
NZ333063A (en) 1996-09-04 2000-12-22 Warner Lambert Co Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
US6294674B1 (en) 2001-09-25
WO1998009957A1 (en) 1998-03-12
EP0929542A1 (en) 1999-07-21
BR9712794A (pt) 1999-12-14
CA2256631A1 (en) 1998-03-12
JP2002514180A (ja) 2002-05-14
AU736347B2 (en) 2001-07-26
HRP970474A2 (en) 1998-12-31
HRP970474B1 (en) 2002-10-31
NZ333064A (en) 2000-11-24
AU4177097A (en) 1998-03-26

Similar Documents

Publication Publication Date Title
US6294674B1 (en) Dibenzofuran sulfonamide matrix metalloproteinase inhibitors
US5387610A (en) Peptide derivatives of collagenase inhibitor
EP0960108B1 (en) Matrix metalloproteinase inhibitors
KR100352316B1 (ko) 메탈로프로테아제억제제로서사용되는술포닐아미노치환히드록삼산유도체
US6117869A (en) Compounds for and methods of inhibiting matrix metalloproteinases
KR20000035917A (ko) 1,4-헤테로고리성 메탈로프로테아제 저해제
KR20000068414A (ko) 매트릭스 메탈로프로테이나제 억제제 및 그의 치료적 용도
BG63967B1 (bg) Сулфонамидни инхибитори на матрични металопротеинази
US5672583A (en) Carboxy-peptidyl derivatives as antidegenerative active agents
ES2216614T3 (es) Sulfonamidas triciclicas y sus derivados como inhibidores de metaloproteinasas de matriz.
CZ195298A3 (cs) Aromatické keto-kyseliny a jejich deriváty jako inhibitory matricových metaloproteináz
SK15462000A3 (sk) Substituované pyrolidínové hydroxamáty ako inhibítory metaloproteázy
KR20010102486A (ko) 알케닐- 및 알키닐-함유 메탈로프로테아제 저해제
JPWO2009001730A1 (ja) βセクレターゼ阻害活性を有する新規化合物
US6624177B1 (en) Matrix metalloproteinase inhibitors and their therapeutic uses
US6583299B1 (en) α-amino-β-sulfonyl hydroxamic acid compounds
KR20020038951A (ko) 베타 이치환된 메탈로프로테아제 저해제
KR20010034168A (ko) 매트릭스 메탈로프로테이나제 억제제
MXPA98009929A (en) Compounds for and a method of inhibiting matrix metalloproteinases
ZA200103605B (en) Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases.
MXPA98009871A (en) Matrix metalloproteinase inhibitors and their therapeutic uses
CZ2001302A3 (cs) Tricyklické sulfonamidy a jejich deriváty jako inhibitory matricových metaloproteináz

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19990303

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20020902

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20040831

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee